(NASDAQ: CLNN) Clene's forecast annual revenue growth rate of 821.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Clene's revenue in 2026 is $200,000.On average, 7 Wall Street analysts forecast CLNN's revenue for 2026 to be $2,771,235, with the lowest CLNN revenue forecast at $1,061,932, and the highest CLNN revenue forecast at $4,946,889. On average, 7 Wall Street analysts forecast CLNN's revenue for 2027 to be $543,627,760, with the lowest CLNN revenue forecast at $2,308,548, and the highest CLNN revenue forecast at $1,586,773,519.
In 2028, CLNN is forecast to generate $1,991,593,931 in revenue, with the lowest revenue forecast at $263,174,492 and the highest revenue forecast at $3,277,313,923.